Therapeutic efficacy of a K5-specific phage and depolymerase against Klebsiella pneumoniae in a mouse model of infection

Терапевтическая эффективность K5-специфичного фага и деполимеразы против Klebsiella pneumoniae в мышиной модели инфекции
Long Chen, Pei Li, Zhongming Tan, Wei Zhang, Genglin Guo, Xiangkuan Zheng, Sixiang Xu, Zhou Yu, Xiayan Qin, Zimeng Hu, Yanfei Yu, Jiale Ma
2024-05-07

K5-specific bacteriophageKlebsiella pneumoniaecapsular polysaccharide depolymerasemurine infection modelphage therapy
Klebsiella pneumoniae has become one of the most intractable gram-negative pathogens infecting humans and animals due to its severe antibiotic resistance. Bacteriophages and protein products derived from them are receiving increasing amounts of attention as potential alternatives to antibiotics. In this study, we isolated and investigated the characteristics of a new lytic phage, P1011, which lyses K5 K. pneumoniae specifically among 26 serotypes. The K5-specific capsular polysaccharide-degrading depolymerase dep1011 was identified and expressed. By establishing murine infection models using bovine strain B16 (capable of supporting phage proliferation) and human strain KP181 (incapable of sustaining phage expansion), we explored the safety and efficacy of phage and dep1011 treatments against K5 K. pneumoniae. Phage P1011 resulted in a 60% survival rate of the mice challenged with K. pneumoniae supporting phage multiplication, concurrently lowering the bacterial burden in their blood, liver, and lungs. Unexpectedly, even when confronted with bacteria impervious to phage multiplication, phage therapy markedly decreased the number of viable organisms. The protective efficacy of the depolymerase was significantly better than that of the phage. The depolymerase achieved 100% survival in both treatment groups regardless of phage propagation compatibility. These findings indicated that P1011 and dep1011 might be used as potential antibacterial agents to control K5 K. pneumoniae infection.
1
Depolymerase treatment outperformed phage therapy and achieved 100% mouse survival regardless of phage-propagation compatibility, supporting both agents as potential treatments for K5 K. pneumoniae infection.
2
P1011 treatment produced 60% survival in mice infected with a strain supporting phage multiplication and reduced bacterial burdens in blood, liver, and lungs.
3
Phage therapy substantially reduced viable bacteria even in infections where the pathogen could not support phage propagation.
4
The K5 capsular polysaccharide-degrading depolymerase dep1011 was identified, expressed, and evaluated as an antibacterial treatment.
5
The newly isolated lytic phage P1011 specifically lysed K5 Klebsiella pneumoniae among 26 tested serotypes.

K5 Klebsiella pneumoniae infection in mice, including bovine strain B16 and human strain KP181

The therapeutic safety and efficacy of lytic phage P1011 and the K5 capsular polysaccharide-degrading depolymerase dep1011, including effects on survival and bacterial burden under phage-propagation-compatible and incompatible conditions

Publication Details
Publication Date
2024-05-07
Journal
Publisher
ISSN
Cited by
40
Access Type
Author Information
Authors
Long Chen
Pei Li
Zhongming Tan
Wei Zhang
Genglin Guo
Xiangkuan Zheng
Sixiang Xu
Zhou Yu
Xiayan Qin
Zimeng Hu
Yanfei Yu
Jiale Ma
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%